These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31539173)

  • 1. Doxorubicin and cyclophosphamide-induced parotitis: A case report.
    Fox-Lewis A; Tairab M; Fulton G; Kuper-Hommel M; Jameson MB
    J Clin Pharm Ther; 2020 Feb; 45(1):211-213. PubMed ID: 31539173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review and assessment of drug-induced parotitis.
    Brooks KG; Thompson DF
    Ann Pharmacother; 2012 Dec; 46(12):1688-99. PubMed ID: 23249870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
    Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
    Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey on gastrointestinal adverse drug reactions of Doxorubicin and Cyclophosphamide combination therapy.
    Jamali J; Dayo A; Adeel A; Qureshi Y; Khan T; Begum S
    J Pak Med Assoc; 2018 Jun; 68(6):926-928. PubMed ID: 30325912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-based adjuvant chemotherapy in breast cancer.
    Montemurro F; Aglietta M
    Lancet; 2010 May; 375(9729):1871; author reply 1871-2. PubMed ID: 20511012
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
    Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
    Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemostimulating properties of cropanol during cytostatics-induced myelosuppression].
    Zhdanov VV; Gol'dberg VE; Khrichkova TIu; Matiash MG; Gur'iantseva LA; Simolina EI; Vysotskaia VV; Suslov NI; Popova NO; Dygaĭ AM
    Eksp Klin Farmakol; 2002; 65(6):37-40. PubMed ID: 12596531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant docetaxel for node-positive breast cancer.
    Ahluwalia MS; Daw HA
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16135845
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant docetaxel for node-positive breast cancer.
    Noronha V
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
    [No Abstract]   [Full Text] [Related]  

  • 16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
    J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.